| 顾佳佳,尹 丽,何 侠.西妥昔单抗在鼻咽癌中的研究进展及临床应用[J].肿瘤学杂志,2016,22(3):230-235. |
| 西妥昔单抗在鼻咽癌中的研究进展及临床应用 |
| Advances of Cetuximab Research and Its Clinical Application in Nasopharyngeal Carcinoma |
| 投稿时间：2015-12-01 |
| DOI：10.11735/j.issn.1671-170X.2016.03.B016 |
|
 |
| 中文关键词: 鼻咽肿瘤 表皮生长因子受体 西妥昔单抗 顺铂 放射疗法 |
| 英文关键词:nasopharyngeal neoplasms epidermal growth factor receptor cetuximab ciaplatin radiotherapy |
| 基金项目:江苏省科技厅临床医学重点专项（BL2014091） |
|
| 摘要点击次数: 2334 |
| 全文下载次数: 720 |
| 中文摘要: |
| 摘 要：鼻咽癌高发于东南亚及我国南方，顺铂为基础的同步放化综合治疗模式下，仍存在约30%的治疗失败，需要寻找新的药物靶点及治疗策略以进一步提高疗效。表皮生长因子受体(epidermal growth factor receptor，EGFR)在超过85%鼻咽癌中呈现高表达，且与不良预后、高转移和治疗抵抗等密切相关。因此，针对EGFR的分子靶向治疗可能进一步提高鼻咽癌的疗效。西妥昔单抗是EGFR的IgG1人鼠嵌合型单克隆抗体，临床研究中与放化疗联合治疗鼻咽癌取得了较好的疗效。体内外研究也表明，西妥昔单抗具有放化疗增敏作用，但具体分子机制仍在探索之中。与西妥昔单抗疗效预测相关的生物标志物也有待开发，以更好实现临床的个体化及精准治疗。文章就西妥昔单抗在鼻咽癌中的研究进展及临床应用作一综述。 |
| 英文摘要: |
| Abstract：Nasopharyngeal carcinoma (NPC) is one of the malignant tumours which is common in southeast part of Asia and south of China. As a standard strategy for locally advanced NPC，cisplatin-based concurrent chemo-radiotherapy can achieve excellent 5-year local control rate，about 30% of patients still fail with local recurrence and distant metastases as the mainly patterns of disease failure. Hence，new therapeutic strategies are urgent to further improve the treatment outcome. Epidermal growth factor receptor (EGFR) has been proved to be over-expressed in more than 85% of NPC tissues and is associated with poor prognosis，metastasis and treatment resistance. The use of monoclonal antibodies to inhibit EGFR becomes an effective approach to improve the overall survival of NPC patients. Ctuximab is the human murine chimeric version of MAb 225. A series of studies have shown that cetuximab combined with chemo-radiotherapy for NPC patients is feasible and well tolerated，which has achieved excellent clinical response. In vivo and vitro studies also proved that cetuximab can enhance the cytotoxic activities of chemotherapeutic agents and radiation therapy，but the molecular mechanism is still unknown. Future studies should aim at defining the predictive markers for response to cetuximab in order to achieve better clinical individual and accurate curative effects. The research progress and clinical application of cetuximab in nasopharyngeal carcinoma are reviewed in this article. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |